Clotrimazole + Gentamicin + Mometasone
845 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 845 |
| Reports involving death | 12 |
| Case-fatality rate (reported events) | 140.0% |
| Distinct species in reports | 4 |
| Distinct breeds in reports | 20 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 3 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Clotrimazole + Gentamicin + Mometasone Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 845 adverse event reports referencing Clotrimazole + Gentamicin + Mometasone, including 12 reports in which the animal died — a 140.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Clotrimazole, Gentamicin, Mometasone. Reported administration routes include Auricular (Otic), Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Clotrimazole + Gentamicin + Mometasone reports are Dog (821 reports), Unknown (17 reports), Cat (5 reports), with Dog accounting for the largest share. Within those species, Unknown (129), Retriever - Labrador (90), Pit Bull (46) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Clotrimazole + Gentamicin + Mometasone are Temporary deafness (459), PR-EAR(S), LESION(S) (275), Loss of hearing (228), Deafness (77). Of the 829 reports with a coded outcome, Ongoing is the leading category at 42.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Clotrimazole + Gentamicin + Mometasone.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.